FibroGen (FGEN) shares have risen sharply in trading today after the company announced the dosing of the first patient in Phase 3 studies in Japan assessing roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD). The event triggers a $10M milestone payment to FibroGen from Astellas. The Phase 3 trials follow two successful Phase 2s there. FibroGen is collaborating with Astellas on the development and commercialization of roxadustat for anemia in CKD patients in Japan, the Commonwealth of Independent States, the Middle East and South Africa.